Primary Sclerosing Cholangitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Cilofexor, HTD1801, NGM282 (Aldafermin)

Posted on
by

Primary Sclerosing Cholangitis Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Cilofexor, HTD1801, NGM282 (Aldafermin)
DelveInsight’s “Primary Sclerosing Cholangitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Primary Sclerosing Cholangitis, historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Primary Sclerosing Cholangitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Primary Sclerosing Cholangitis pipeline products will significantly revolutionize the Primary Sclerosing Cholangitis market dynamics.  

 

Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis (PSC) is a rare cholestatic disorder of the liver, with strictures in the bile ducts leading to cirrhosis of the liver in a proportion of patients. The etiology of PSC is unknown; thus, PSC is generally considered as an idiopathic disease. Primary sclerosing cholangitis is commonly associated with inflammatory bowel disease and increased risk of cholangitis carcinoma, gall bladder cancer, colorectal cancer, and hepatocellular carcinoma. Medical therapies are primarily aimed at symptom management and disease-modifying therapies are limited. Endoscopic therapies are used in patients with dominant strictures and liver transplantation is a last resort.

 

Some of the key facts of the Primary Sclerosing Cholangitis Market Report: 

  • The Primary Sclerosing Cholangitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • The United States accounted for the largest market size of Primary Sclerosing Cholangitis, in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. 
  • According to Gochanour et al., the prevalence in the United States is estimated to be 1 to 16 per 100,000 
  • According to Aune et al., Primary Sclerosing Cholangitis is a rare disease with an incidence of 0.4–0.7 cases per 100,000 in the UK and a prevalence of 3.9–16.2 per 100,000 
  • Key Primary Sclerosing Cholangitis Companies: Gilead Sciences, High Tide Pty Ltd, NGM Biopharmaceuticals, and others 
  • Key Primary Sclerosing Cholangitis Therapies: Cilofexor, HTD1801, NGM282 (Aldafermin), and others 
  • The Primary Sclerosing Cholangitis epidemiology based on gender analyzed that males are affected more as compared to females in case of Primary Sclerosing Cholangitis

 

Get a Free sample for the Primary Sclerosing Cholangitis Market Report 

 

Key benefits of the Primary Sclerosing Cholangitis Market report:

  1. Primary Sclerosing Cholangitis market report covers a descriptive overview and comprehensive insight of the Primary Sclerosing Cholangitis Epidemiology and Primary Sclerosing Cholangitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Primary Sclerosing Cholangitis market report provides insights on the current and emerging therapies.
  3. Primary Sclerosing Cholangitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Primary Sclerosing Cholangitis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Primary Sclerosing Cholangitis market.

 

Discover more about therapies set to grab major Primary Sclerosing Cholangitis market share @ Primary Sclerosing Cholangitis market forecast 

 

Primary Sclerosing Cholangitis Epidemiology Segmentation:

The Primary Sclerosing Cholangitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Primary Sclerosing Cholangitis
  • Prevalent Cases of Primary Sclerosing Cholangitis by severity
  • Gender-specific Prevalence of Primary Sclerosing Cholangitis
  • Diagnosed Cases of Episodic and Chronic Primary Sclerosing Cholangitis 

 

Primary Sclerosing Cholangitis Market  

The dynamics of the Primary Sclerosing Cholangitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as HTD1801, NGM282, and others during the forecasted period 2019-2032. 

 

Download the report to understand which factors are driving Primary Sclerosing Cholangitis epidemiology trends @ Primary Sclerosing Cholangitis Epidemiological Insights 

 

Primary Sclerosing Cholangitis Market Drivers

  • Market Opportunity
  • Increase in research activities
  • Genome-wide association studies for Primary Sclerosing Cholangitis

 

Primary Sclerosing Cholangitis Therapies and Key Companies

  • Cilofexor: Gilead Sciences
  • HTD1801: High Tide Pty Ltd
  • NGM282 (Aldafermin): NGM Biopharmaceuticals 

 

Scope of the Primary Sclerosing Cholangitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Primary Sclerosing Cholangitis Companies: Gilead Sciences, High Tide Pty Ltd, NGM Biopharmaceuticals, and others
  • Key Primary Sclerosing Cholangitis Therapies: Cilofexor, HTD1801, NGM282 (Aldafermin), and others
  • Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
  • Primary Sclerosing Cholangitis Market Dynamics:  Primary Sclerosing Cholangitis market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Primary Sclerosing Cholangitis  Market Access and Reimbursement 

Primary Sclerosing Cholangitis Market Barriers

  • Lack of country specific epidemiology data
  • Shortcomings of trials
  • Unavailability of biomarkers

Table of Contents 

1. Primary Sclerosing Cholangitis Market Report Introduction

2. Executive Summary for Primary Sclerosing Cholangitis

3. SWOT analysis of Primary Sclerosing Cholangitis

4. Primary Sclerosing Cholangitis Patient Share (%) Overview at a Glance

5. Primary Sclerosing Cholangitis Market Overview at a Glance

6. Primary Sclerosing Cholangitis Disease Background and Overview

7. Primary Sclerosing Cholangitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Primary Sclerosing Cholangitis 

9. Primary Sclerosing Cholangitis Current Treatment and Medical Practices

10. Primary Sclerosing Cholangitis Unmet Needs

11. Primary Sclerosing Cholangitis Emerging Therapies

12. Primary Sclerosing Cholangitis Market Outlook

13. Country-Wise Primary Sclerosing Cholangitis Market Analysis (2019–2032)

14. Primary Sclerosing Cholangitis Market Access and Reimbursement of Therapies

15. Primary Sclerosing Cholangitis Market drivers

16. Primary Sclerosing Cholangitis Market barriers

17.  Primary Sclerosing Cholangitis Appendix

18. Primary Sclerosing Cholangitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Primary Sclerosing Cholangitis treatment, visit @ Primary Sclerosing Cholangitis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/